Esperion Therapeutics, a biopharmaceutical company based in Ann Arbor, MI, has announced that TransGenRx, a Baton Rouge, LA, company, will produce protein-based therapeutics to be used in Esperion’s research. Esperion is developing therapies to treat cardio-metabolic disease including therapies based on HDL, the body’s “good” cholesterol, which has been shown to play an important role in lipid management. TransGenRx will coordinate production of protein-based therapies. “While HDL continues to show great promise in the treatment of cardiovascular disease, there have been significant challenges in the development of protein-based drug therapies, Roger Newton, Esperion’s president and CEO, said in a prepared statement.
Author: Howard Lovy
Howard Lovy is a veteran journalist who has focused primarily on technology, science and innovation during the past decade.
In 2001, he helped launch Small Times Magazine, a nanotech publication based in Ann Arbor, MI, where he built the freelance team and worked closely with writers to set the tone and style for an emerging sector that had never before been covered from a business perspective. Lovy's work at Small Times, and on one of the first nanotechnology-themed blogs, helped him earn a reputation for making complex subjects understandable, interesting, and even entertaining for a broad audience. It also earned him the 2004 Prize in Communication from the Foresight Institute, a nanotech think tank.
In his freelance work, Lovy covers nanotechnology in addition to technological innovation in Michigan with an emphasis on efforts to survive and retool in the state's post-automotive age. Lovy's work has appeared in many publications, including Wired News, Salon.com, the Wall Street Journal, The Detroit News, The Scientist, the Forbes/Wolfe Nanotech Report, Michigan Messenger, and the Ann Arbor Chronicle.
View all posts by Howard Lovy